Favipiravir may be an effective option for treating infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), in maintenance dialysis.1 There have been few reports of favipiravir administration in hemodialysis patients. We administered favipiravir to a hemodialysis patient with COVID-19 and found that blood concentrations of favipiravir were similar to those seen in patients not receiving dialysis.